Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 , an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
Alvopetro Announces Q3 2025 Financial Results and an Operational Update Including Record October Sales
Altech Batteries Ltd Service Data Confirms Exceptionally Low Failure Rate for Sodium-Nickel-Chloride Batteries
Allied Critical Metals Expands Santa Helena Breccia with 6.0 Metres of 1.02% WO3 Intercept at Borralha
